SEC Form 4 · accession 0001225208-15-006385
Edwards Lifesciences Corp · EW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick B Verguet
Officer — CVP, Europe
Period of report
Feb 26, 2015
Accepted (ET)
Mar 2, 2015 · 6:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001099800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 26, 2015 | M | 10,000 | $31.47 | A | 59,053 | D | |
| Common StockF2,F1 | Feb 26, 2015 | S | 10,000 | $134.75 | D | 49,053 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Acquire)F1 | $31.47 | Feb 26, 2015 | M | 10,000 | D | May 7, 2010 | May 6, 2016 | Common Stock | 10,000 | 65,000 | D |
Explanation of responses
- F1This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.
- F2This transaction was executed in multiple trades at prices ranging from $134.50 to $135.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.